Results 91 to 100 of about 386,064 (216)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Spectrum of Chronic Gastritis Based on Morphological Examination of Gastric Biopsies

Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Aim: in the retrospective study to assess the frequency of various gastritis variants based on the results of morphological examination of gastric biopsies over a 5-year observation period.Methods.
А. S. Tertychnyy, Т. L. Lapina, D. Р. Nagornaya, N. V. Pachuashvili, А. Р. Kiryukhin, А. А. Fedorenko, Р. V. Pavlov, D. D. Protsenko, V. Т. Ivashkin   +8 more
doaj   +1 more source

Clinicopathological Features of Gastric Cancer with Autoimmune Gastritis

Biomedicines, 2022
Most gastric cancers develop in patients with chronic gastritis. Chronic gastritis can be classified into two major subtypes: Helicobacter pylori (H. pylori)-induced gastritis and autoimmune gastritis (AIG). Whereas H.
Junya Arai, Ryota Niikura, Yoku Hayakawa, Nobumi Suzuki, Yoshihiro Hirata, Tetsuo Ushiku, Mitsuhiro Fujishiro   +6 more
doaj   +1 more source

Sialendoscopic management of autoimmune sialadenitis: a review of literature [PDF]

, 2017
Autoimmune diseases of major salivary glands include Sjögren's syndrome and a complex of disorders classified as immunoglobulin G4-related diseases.
DE VINCENTIIS, Marco, DE VIRGILIO, Armando, Fusconi, Massimo, Gallo, Andrea, Greco, Antonio, Martellucci, Salvatore, Pagliuca, Giulio   +6 more
core   +2 more sources

The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus

Histopathology, EarlyView.
The new OLGIMA method for histological gastric cancer risk assessment is based on the severity of glandular atrophy and intestinal metaplasia, in both antrum and corpus, according to the Updated Sydney classification. The highest score of either atrophy or intestinal metaplasia from each location will be used for the final OLGIMA stage.
Pedro Genaro Delgado Guillena, Miriam Cuatrecasas, Sheyla Montori, Nayra Felipez Varela, Joan Llach, Iva Archilla, Pablo Florez‐Diez, Eva Barreiro‐Alonso, Javier Tejedor‐Tejada, Raquel Vicente, M Teresa Soria, Alaín Huerta, Silvia Patricia Ortega, Henar Nuñez, Oliver Patrón, Carolina Mangas, Diana Zaffalon, Luis Hernández, Luis Enrique Yip, Gadea Hontoria, Gonzalo Hijos, Maria Jose Domper‐Arnal, Sara Zarraquiños, Alberto Herreros De Tejada, Alicia Córdoba, Anabella Cuestas, Glòria Fernández‐Esparrach, Leticia Moreira, Eduardo Albéniz, on behalf of EpiGASTRIC/EDGAR Consortium, Joan Llach, Sheyla Montori, Anabella Cuestas, Gloria Fernandez‐Esparrach, Nayra Felipez Varela, Fermín Estremera‐Arevalo, Marta Gómez Alonso, Juan José Vila Costas, Victoria Busto Bea, Juan Carrascosa Gil, Vanesa Jusué Irurita, Alicia Córdoba Iturriagagoitia, Concepción Llanos Chavarri, Irene Amat Villegas, Gregorio Aisa Rivera, Irene Fernández de los Reyes, Gina de Lima Piña, Miguel Ángel Resano, Adriana Yague Hernando, Cristina Caballero Martínez, Alfredo López Cousillas, Miriam Cuatrecasas, Pedro Genaro Delgado Guillena, Javier Tejedor, Elena Arruebo, Silvia Patricia Ortega, Henar Nuñez, Pilar Diez, Diana Zaffalon, Luis Hernández, Gadea Hontoria, Rosa Maria Saíz, Gonzalo Hijos, María Jose Domper, Sara Zarraquiños, Astrid Irene, Alberto Herreros, Diego de Frutos, Fatima Valentin, Jose Santiago, Virginia Piñol, Adelina García, Alicia Martín‐Lagos, Pablo Florez, Eva Barreiro, Adolfo Suarez, Raquel Vicente, M Teresa Soria, Cristina Polo, Carmen Yagüe, Alain Huerta, Oliver Patrón, David Tello, Carolina Mangas, Eva Serrano, Juan Martínez, Rodrigo Jover, Raquel Grajal, Luis Enrique Yip, Patricia Gonçalves, Jenifer Muñoz, Cristina Herrera‐Pariente, Laia Bonjoch, Sergi Castellví‐Bel, Dulce Momblan, Tamara Saurí, Irina Luzko, Elisa Cantú‐Germano, Angels Gines, Ignasi Elizalde, Francesc Balaguer, Angelez Perez‐Aisa, Jennifer Hinojosa, Coral Tejido, Laura Rivas, María Francisco, Manu Puga, Franco Baiocchi, Cristina Alejandra Sánchez, Alba Pereiros, Joaquin Cubiella, Alejandro Ledo, Ma Victoria Alvarez, Marta Garzón, Juan Manuel Martín, Salvador Sobrino, Ana García‐Rodríguez, Ines Gil, Alazne Aguirre, Ainara Maiz, Ines Ariño, María Dolores Pico, Beatriz de Riba, Goretti Hernández, Eduardo Albéniz, Leticia Moreira   +125 more
wiley   +1 more source

Hematological manifestations of autoimmune gastritis

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2016
Aim of investigation. To estimate hematological disorders in patients with high titer of anti-parietal cell antibodies (APCA). Material and methods. Overall 71 patient with high serum APCA titer were included in original study.
Ye. A. Losik, V. T. Ivashkin
doaj   +1 more source

Autoimmune Atrophic Gastritis: A Clinical Review

Cancers
Simple Summary Autoimmune atrophic gastritis can lead to serious conditions, including malabsorption and vitamin deficiencies, that may cause anemia, neurological disorders, and gastric malignancies.
Chiara Castellana, L. Eusebi, E. Dajti, Veronica Iascone, A. Vestito, Pietro Fusaroli, L. Fuccio, Antonietta D’Errico, R. Zagari   +8 more
semanticscholar   +1 more source

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC). Methods Of 835 patients with uHCC treated
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Ryu Sasaki, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Tomotake Shirono, Yuki Kanayama, Hisamitsu Miyaaki, Sohji Nishina, Tetsuji Takayama, Hideki Kobara, Motoyuki Otsuka, Taro Takami, Takumi Kawaguchi, Hiroki Kawashima, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +24 more
wiley   +1 more source

Antibiotic‐mediated immune modulation in periodontitis

Periodontology 2000, EarlyView.
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez, R. M. Arce, Camila Pinheiro Furquim, Cristiane Gonçalves, Alpdogan Kantarci, Magda Feres, Nidia C. Castro dos Santos   +6 more
wiley   +1 more source

Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report

DEN Open, Volume 6, Issue 1, April 2026.
Abstract A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration.
Satoshi Kosaka, Miki Kamiyama, Masahiro Ochi   +2 more
wiley   +1 more source